Abstract CAR-T therapy is a powerful treatment for pediatric B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of bridging therapy prior to CAR-T infusion on patient outcomes remains insufficiently explored. In this retrospective study of patients with relapse/refractory B-ALL (N = 103), we compared outcomes across different bridging therapy groups: Low-Intensity Chemotherapy (LIC, N = 50), Immunotherapy (N = 20), or High-Intensity Chemotherapy (HIC, N = 33).
Pere Barba
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Pere
Contact Pere, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy
|
By Sergi Camarillas, Anna Alonso-Saladrigues, Víctor Navarro Verified, Júlia Marsal, Javier Delgado, Blanca Herrero, Claire Roddie, Veit Bücklein, Marion Subklewe, Mario Sánchez-Salinas, Ana Martin, Ana Martín, Anna Torrent, Antonio Pérez-Martínez, Gloria Iacoboni, Susana Rives, Pere Barba, Águeda Molinos, Alex Rampotas, Berta González-Martínez
|
Nature
Verified
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF. USD 39.95 Prices may be subject to local taxes which are calculated during checkout References Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al.
Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party
|
By Gloria Iacoboni, Pere Barba, Irma Khvedelidze, Maud Ngoya, Paolo Corradini, Pierre Sesques, Marion Subklewe, Izaskun Zeberio, Alejandro Martín García-Sancho, Tom van Meerten, Robin Sanderson, Bertram Glass, Anna Sureda, Peter Dreger, Olivier Hermine, Ali Bazarbachi, Gilles Crochet, Jaroslaw Dybko
|
Nature
Verified
Chimeric antigen receptor T-cell therapy (CART) is a standard approach for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) based on the ZUMA-2 and TRANSCEND NHL 001 trial results, which led to the regulatory approval of brexucabtagene autoleucel (brexu-cel) and lisocabtagene maraleucel (liso-cel), respectively [1, 2].
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Pere
Contact Pere, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack